Sinonasal Undifferentiated Carcinoma (SNUC)

Sinonasal Undifferentiated Carcinoma (SNUC), explained simply

Everything a patient or caregiver wants to understand: what sinonasal undifferentiated carcinoma (snuc) is, how doctors describe its stage, the standard treatment plan, how radiation works, and the research shaping care today.

On this page

Watch: the CureRays® explainer series

Watch Dr. Hess explain radiation therapyPlain-language videos on how radiation works, what treatment feels like, and what to expect — on the CureRays® YouTube channel.

Prefer to read? The full guide below is complete on its own, with tables you can revisit any time.

What is sinonasal undifferentiated carcinoma (snuc)?

Sinonasal undifferentiated carcinoma (SNUC) is a rare and aggressive cancer that arises in the nasal cavity and paranasal sinuses. Under the microscope its cells look very primitive ('undifferentiated'), meaning they have lost the features that would show what tissue they came from, which is part of why it grows quickly. Because it sits close to the eyes, the base of the skull, and the brain, it can grow into these structures and often causes a blocked nose, nosebleeds, facial pain or pressure, or vision changes, and it is frequently advanced when found. Treatment is intensive and team-based, typically combining chemotherapy, radiation, and surgery. Modern approaches that start with chemotherapy to shrink the tumor have improved outcomes, and care is best delivered at experienced centers.

In one line: Sinonasal undifferentiated carcinoma is a rare, fast-growing cancer of the nasal cavity and sinuses that is treated aggressively by combining chemotherapy, radiation, and surgery, with radiation a central part of cure because of its delicate location near the eyes and brain.

The main types

Doctors group sinonasal undifferentiated carcinoma (snuc) by where it starts and how it behaves:

TypeWhat it means, simply
Classic SNUCThe core diagnosis: a high-grade, undifferentiated carcinoma of the sinonasal region with no specific tissue features and aggressive behavior.
Related high-grade sinonasal cancersNewer testing now separates look-alikes such as SMARCB1-deficient or NUT carcinomas from true SNUC, because some have specific markers and tailored treatments; expert pathology is essential.

Staging, in plain terms

SNUC is staged with the TNM system used for sinonasal cancers — how far the tumor has grown and which structures it involves (T), whether it has spread to neck lymph nodes (N), and whether it has spread to distant organs (M). Because SNUC tends to be large and to invade nearby structures like the eye socket and skull base, most cases are diagnosed at an advanced T stage, which is why treatment is intensive from the start.

Head-and-neck TNM (sinonasal)What it generally means
Localized (less common)Confined to the sinonasal region without invasion of critical structures. Treated aggressively with combined therapy, with the best chance of cure.
Locally advancedGrown into the eye socket, skull base, or brain coverings — the most common presentation. Treated with chemotherapy, radiation, and surgery in a planned sequence.
Nodal or distant spreadSpread to neck lymph nodes or distant organs. Treated with systemic chemotherapy and radiation, with surgery selected case by case.
Plain-language takeaway: Staging tells your team how much disease there is and where — but your tumor's biology matters too. Two people described the same way can still have different plans, and that's a good thing.

The standard of care

Sinonasal Undifferentiated Carcinoma (SNUC) is almost always treated by a team that may include a surgeon, a medical oncologist, and a radiation oncologist, combining therapies for the best result. The usual building blocks are:

Induction chemotherapy first

Many centers now start with chemotherapy to shrink the tumor and test how well it responds. The response helps decide whether to follow with chemoradiation alone or with surgery, and it has been linked to better outcomes.

Radiation therapy (central to treatment)

High-dose, precisely shaped radiation treats the tumor region and is a cornerstone of cure, given with chemotherapy and/or after surgery to control disease around the eyes and skull base.

Surgery (selected cases)

Removing the tumor — endoscopically or with a combined approach — is used when it can be done safely and when the team judges it will improve control, often after chemotherapy has shrunk the tumor.

Chemotherapy with radiation

Chemotherapy is given alongside radiation to make it more effective and to treat microscopic spread, reflecting the cancer's aggressive nature.

How radiation treatment works

Radiation damages the DNA inside cancer cells so they can no longer grow and divide, which is especially effective against fast-dividing tumors like SNUC. Because the cancer sits next to the eyes, optic nerves, and brain, radiation must be shaped very precisely; intensity-modulated radiation and proton therapy concentrate the dose on the tumor while sparing vision and brain function. Radiation is usually combined with chemotherapy — which makes the radiation more effective — and is delivered after or instead of surgery depending on the plan. Treatment is painless during delivery, given over several weeks of daily sessions, and external-beam radiation leaves no radioactivity in the body.

The main ways radiation is delivered for sinonasal undifferentiated carcinoma (snuc):

Intensity-modulated radiation (IMRT)

Beams are sculpted around the eyes, optic nerves, and brain to deliver a high tumor dose while protecting vision and brain tissue.

Proton therapy

Proton beams stop at a chosen depth and spare tissue beyond the target, helping limit dose to the brain and eyes in this delicate region.

Concurrent chemoradiation

Radiation is paired with chemotherapy so the two together damage the fast-dividing cancer cells more effectively than either alone.

Latest studies shaping care

Care keeps improving — often toward getting the same excellent results with less burden on patients. A few developments:

Induction chemotherapy guides treatment: Studies report that starting with chemotherapy and measuring the tumor's response helps select treatment: good responders often do well with chemoradiation, and response to induction has been associated with improved survival.[1]

MD Anderson and multi-center SNUC treatment-sequencing studies

Refining the diagnosis with molecular markers: Modern pathology now separates true SNUC from molecularly defined look-alikes (such as SMARCB1-deficient and NUT carcinomas), allowing more accurate diagnosis and, for some, targeted approaches.[2]

American Journal of Surgical Pathology / WHO sinonasal tumor classification

Combined-modality therapy improves control: Outcome series support aggressive combined treatment — chemotherapy, radiation, and selective surgery at experienced centers — as the approach giving the best local control for this aggressive cancer.[3]

Head & Neck / International Journal of Radiation Oncology outcome series

Common questions

Why is treatment so intensive? SNUC grows quickly and is usually advanced when found, often pressing against the eyes, skull base, or brain. Combining chemotherapy, radiation, and sometimes surgery gives the best chance of controlling it, which is why care is aggressive and team-based from the start.

Will my vision be affected? It can be, because the cancer and its treatment involve the area around the eyes. Teams use precise radiation techniques such as IMRT and proton therapy specifically to protect the eyes and optic nerves while still treating the tumor effectively. Your doctors will discuss the individual balance of risks.

Does the exact diagnosis matter? Yes. Several rare sinonasal cancers can look like SNUC under the microscope. Modern molecular testing can distinguish true SNUC from related tumors (such as NUT or SMARCB1-deficient carcinoma), and the precise diagnosis can change the recommended treatment — so expert pathology review is important.

References

Numbered sources for the studies cited above. Links open the primary publication on PubMed or the publisher’s site.

  1. MD Anderson and multi-center SNUC treatment-sequencing studies (no indexed identifier — see your care team)
  2. American Journal of Surgical Pathology / WHO sinonasal tumor classification (no indexed identifier — see your care team)
  3. Head & Neck / International Journal of Radiation Oncology outcome series (no indexed identifier — see your care team)
Medical disclaimer: This guide is general patient education, not medical advice, and reflects widely accepted standards as of 2026. Your situation is unique — always discuss your diagnosis and options with your own care team. CureRays clinicians are here to help you understand your choices.

Talk to a CureRays radiation oncologist Back to all guides